About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
J
Results of the Phase 1 Study of Pralatrexate Plus Romidepsin: Highly Effective in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma
By
Jennifer Amengual
133 views
October 17, 2018
0 Comments
Login to view comments.
Click here to Login
Featured Video
06:51
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…
Feat.
D. Tremblay
Featured Video
15:14
Icahn School of Medicine at Mount Sinai
Safety Profile of Ruxolitinib in Patients With MF
Feat.
D. Tremblay
Related Content
AUTOPLAY
ON
55:12
University of Colorado Division of Hematology
A Personalized Approach for T-Cell Lymphomas
Feat.
B. Haverkos
19:38
19th Annual International Ultmann Chicago Lymphoma Symposium
T-Cell Lymphomas: Impact of Classification on Treatment
Feat.
N. Mehta-Shah
21:53
Penn Medicine's 2023 Updates in Care of the Hematologic Malignancies Patient
Therapeutic Advances in T-Cell Lymphomas
Feat.
S. Barta
11:01
i3 Health
Diagnosis and Evidence-Based Management of T-Cell Lymphoma
Feat.
A. Goodman
34:28
Indy Hematology Review
Advancing Therapeutic Outcomes in Aggressive B and T Cell Lymphomas
Feat.
T. Phillips
10:50
SOHO 2023 Eleventh Annual Meeting
SOHO 2023 Next Questions: T-Cell Lymphoma
Feat.
M. Lunning
18:10
SOHO Brazil 2023
2023 SOHO® Brazil: "Moving Beyond CHOP/CHOEP - How Disease Feat…
Feat.
A. Moskowitz
11:27
Penn Medicine Abramson Cancer Center
EHA and ASCO 2022 Penn Medicine Updates on Targeted Therapies and Im…
Feat.
S. Barta
10:33
SOHO 2023 Eleventh Annual Meeting
SOHO 2023: A Multidisciplinary Approach to the Management of Mycosis…
Feat.
C. Querfeld
12:55
Yale Cancer Center
ASH 2022 Highlights: T-Cell Lymphoma and Hodgkin Lymphoma
Feat.
T. Sethi
41:01
University of Colorado Division of Hematology
Recent Updates in Lymphoma: PD-1 mAbs and Novel Cell Therapy in cHL …
Feat.
B. Haverkos
17:35
RWJBarnabas Health Rutgers Cancer Institute of New Jersey
Lymphoma During Pregnancy
Feat.
A. Evens
16:35
SOHO 2022 Tenth Annual Meeting
SOHO 2022: Integrating Novel Agents Into the Management of Cutaneous…
Feat.
P. Allen
41:39
19th Annual International Ultmann Chicago Lymphoma Symposium
Venous Thromboembolism in Lymphoma: Risk Stratification, Prophylaxis…
Feat.
K. Cohen
18:23
VCU Massey Cancer Center
VCU Health Updates on Extranodal Lymphomas
Feat.
V. Yazbeck
19:45
Penn Medicine Abramson Cancer Center
Therapeutic Advances in T-Cell Lymphoma
Feat.
S. Barta
18:24
SOHO 2022 Tenth Annual Meeting
SOHO 2022: Challenging Cases in Rare T-Cell Lymphomas
Feat.
S. Barta
21:21
Society of Hematologic Oncology Ninth Annual Meeting (SOHO 2021)
SOHO 2021 Treatment Updates on Advanced CTCL
Feat.
L. Pinter-Brown
08:38
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)
2020 SOHO MAVORIC Update on R/R CTCL: What Is the Impact of Concomit…
Feat.
L. Geskin
20:07
SOHO Highlights: State of the Art and Next Questions
R/R PTCL State of the Art: Allo-SCT vs. Auto-SCT? Can Pralatrexate C…
Feat.
K. Savage
